The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. by �끂�꽦�썕 et al.
Vol.:(0123456789) 
Gastric Cancer (2019) 22:113–122 
https://doi.org/10.1007/s10120-018-0847-5
ORIGINAL ARTICLE
The clinical implications of FDG-PET/CT differ according to histology 
in advanced gastric cancer
Hong Jae Chon1,2 · Chan Kim1  · Arthur Cho3 · Yoo Min Kim4 · Su Jin Jang5 · Bo Ok Kim6 · Chan Hyuk Park7 · 
Woo Jin Hyung8 · Joong Bae Ahn9 · Sung Hoon Noh8 · Mijin Yun3 · Sun Young Rha9
Received: 23 February 2018 / Accepted: 4 June 2018 / Published online: 9 June 2018 
© The Author(s) 2018
Abstract
Background The prognostic impact of preoperative 18F-FDG PET/CT in advanced gastric cancer (AGC) remains a matter of 
debate. This study aims to evaluate the prognostic impact of  SUVmax in preoperative 18F-FDG PET/CT of AGC according to 
histologic subtype, with a focus on the differences between tubular adenocarcinoma and signet ring cell (SRC) carcinoma.
Methods As a discovery set, a total of 727 AGC patients from prospective database were analyzed according to histologic 
subtype with Cox proportional hazard model and p-spline curves. In addition, another 173 patients from an independent 
institution was assessed as an external validation set.
Results In multivariate analysis, high  SUVmax in preoperative 18F-FDG PET/CT of AGC was negatively correlated with 
disease-free survival (DFS) and overall survival (OS) in patients with diffuse type (DFS: HR 2.17, P < 0.001; OS: HR 2.47, 
P < 0.001) or SRC histology (DFS: HR 2.26, P = 0.005; OS: HR 2.61, P = 0.003). This negative prognostic impact was not 
observed in patients with intestinal type or well or moderately differentiated histology. These findings have been consist-
ently confirmed in a validation set. The p-spline curves also showed a gradual increase in log HR as  SUVmax rises only for 
SRC histology and for diffuse-type AGC. Finally, a novel predictive model for recurrence of AGC with diffuse type or SRC 
histology was generated and validated based on the preoperative  SUVmax.
Conclusions Preoperative high  SUVmax of AGC is a poor prognostic factor in those with diffuse type or SRC histology. This 
study is the first to demonstrate the differential prognostic impact of preoperative PET/CT  SUVmax in AGC according to 
histologic subtype and provide a clue to explain previous discrepancies in the prognostic impact of preoperative PET/CT in 
AGC. Prospective studies are required to validate the role of preoperative  SUVmax in AGC.
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Introduction
F-18 fluoro-2-deoxyglucose positron emission tomogra-
phy/computed tomography (18F-FDG PET/CT) has become 
an indispensable method for the diagnosis, staging, and 
response evaluation of many malignancies [1–3]. In gastric 
cancer (GC), 18F-FDG PET/CT is a useful tool for the diag-
nosis of recurrent disease after curative surgery [4–7]. How-
ever, the role of preoperative 18F-FDG PET/CT is not yet 
fully established. While the National Comprehensive Cancer 
Network guidelines recommend the use of preoperative 18F-
FDG PET/CT in GC patients to rule out distant metastasis, 
the prognostic impact of preoperative 18F-FDG PET/CT 
remains a matter of debate. Several reports suggest a poten-
tial prognostic role for preoperative 18F-FDG PET/CT, while 
others argue against this [8–10]. These discrepancies may be 
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due in part to small sample sizes and heterogeneous patient 
populations in different studies. Notably, 18F-FDG PET/CT 
has low sensitivity in detecting early GC (EGC) and signet 
ring cell (SRC) GC, but many previous studies overlooked 
this, including heterogeneous populations in the studies and 
analyzing the clinical characteristics of the population as a 
whole. Because SRC GC is a unique histologic subtype of 
GC with a distinct tumor biology and bioenergetics, it should 
be analyzed separately [11–14].
The present study evaluated the prognostic impact of 
 SUVmax in preoperative 18F-FDG PET/CT of advanced GC 
(AGC) according to histologic subtype, with a focus on 
the differences between tubular adenocarcinoma and SRC 
carcinoma.
Materials and methods
Patient selection
Between January 2006 and December 2013, patients with 
GC who underwent 18F-FDG-PET/CT and subsequent cura-
tive surgical resection at Yonsei Cancer Center, Severance 
Hospital, Seoul, Korea, were enrolled in the study. A pre-
designed data collection format was utilized to extract data 
from a prospectively maintained database. The main eligi-
bility criteria were as follows: (1) pathologically confirmed 
AGC of tubular adenocarcinoma or SRC-histologic subtype; 
(2) available documented information regarding the primary 
tumor site, postoperative pathological stage, surgery, recur-
rence, and survival; and (3) patients who received curative 
resection including those who presented with enlarged par-
aaortic lymph nodes having radical surgical resection with 
a curative aim accompanied by paraaortic lymph node dis-
section. The main exclusion criteria were as follows: (1) 
patients with EGC; (2) patients who received neoadjuvant 
chemo- or radio-therapy; and (3) patients with multiple 
primary cancers. After applying these criteria, 727 of the 
original 1605 patients were included in the final analysis 
(Fig. S1). The pathological stage was classified according 
to the American Joint Committee on Cancer (AJCC) staging 
manual (7th edition). This study was approved by the Insti-
tutional Review Board of Severance Hospital (#2015-1751-
001). For a validation cohort, AGC patients who underwent 
preoperative 18F-FDG-PET/CT and curative surgical resec-
tion at CHA Bundang Medical Center, Seongnam, Korea, 
between March 2007 and February 2014, were enrolled in 
the study. Data acquisition and analysis were adopted identi-
cally as in the aforementioned institution.
The WHO and the Lauren classifications were used for 
the histopathological evaluation of surgical specimens. 
Tubular adenocarcinoma was additionally classified as being 
well, moderately, or poorly differentiated according to the 
WHO classification. Accordingly, we divided the patients 
into three groups for further analyses: well or moderately 
differentiated (WMD), poorly differentiated (PD), and SRC. 
In terms of the Lauren classification, the tumors were clas-
sified as intestinal, diffuse, or mixed type.
18F‑FDG PET/CT and image analyses
All 18F-FDG PET/CT were performed with either the Dis-
covery STe PET/CT (GE Healthcare, Milwaukee, WI, USA) 
or the Biograph TruePoint 40 PET/CT (Siemens Health-
care, Erlangen, Germany). All patients fasted for at least 
6 h before the scan, and the glucose level in the peripheral 
blood of all patients was confirmed to be 140 mg/dL or less 
before 18F-FDG injection. Approximately, 5.5 MBq 18F-
FDG/kg body weight was administered intravenously 1 hour 
before image acquisition. After the initial low-dose com-
puted tomography (CT) (Discovery STe: 30 mA, 140 kVp, 
Biograph TruePoint: 36 mA, 120 kVp), standard PET/CT 
imaging was performed from the neck to the proximal thighs 
with acquisition times of 2.5 min/bed position for the Bio-
graph Truepoint 40 PET/CT and 3 min/bed position for the 
Discovery STe scanner in three-dimensional mode. Images 
were then reconstructed using ordered subset expectation 
maximization (2 iterations, 20 subsets).
The images were retrospectively reviewed on a GE AW 
4.0 workstation by two experienced nuclear medicine spe-
cialists (A.C. and M.Y.) who were unaware of the patients’ 
clinical information, except for the diagnosis of GC. The 
evaluation of 18F-FDG PET/CT images was performed in 
two steps. First, 18F-FDG PET/CT images of all patients 
were visually assessed and the patients were classified as 
positive or negative with respect to 18F-FDG uptake in the 
primary tumor. Lesions showing focally increased 18F-
FDG uptake that exceeded the uptake in the surrounding 
stomach wall and corresponding cancer lesions as observed 
by contrast-enhanced CT images and gastroduodenoscopy 
were classified as positive 18F-FDG uptake. Focally or dif-
fusely increased 18F-FDG that was indistinguishable from 
physiological gastric wall uptake was judged to be negative 
18F-FDG uptake. After the visual assessment, the maximum 
standardized uptake value  (SUVmax) of the primary lesion 
was obtained and recorded for semi-quantitative analysis.
For the validation cohort, the PET/CT imaging for 173 
AGC patients from CHA Bundang Medical Center was per-
formed with Biograph mCT 128 scanner (Siemens Medical 
Solutions, Knoxville, TN, USA). Initial low-dose CT scans 
for attenuation correction (120 kV, 120 mA, 3 mm section 
width, 3 mm collimation) and PET/CT scans of same area 
with three-dimensional mode were acquired consecutively. 
Images were reconstructed on 400 × 400 matrices using the 
TrueX algorithm plus time-of-flight (TOF) reconstruction 
and analyzed using a dedicated workstation and software 
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(Syngo.via, Siemens Medical Solutions, Knoxville, TN, 
USA). Unless otherwise stated, all other methods applied 
for image acquisition and data analysis were adopted identi-
cally as in the aforementioned institution.
Statistical analysis
The cut-off date was December 31, 2015. The mean  SUVmax 
was compared according to the patients’ basic demographic 
and clinical characteristics using independent sample t tests 
or analysis of variance. For pairwise comparisons of each 
level of categorical variables, the statistical significance was 
adjusted for inflated type I errors from multiple comparisons 
using the Bonferroni method.
Relapse-free survival (RFS) was measured from the time 
of surgery to initial tumor relapse (either local or distant) or 
death from any cause, and overall survival (OS) was calcu-
lated as the time from surgery to death from any cause or 
to the last follow-up date. Survival outcomes of the group 
with high  SUVmax were compared with survival outcomes 
of the group with low  SUVmax based on the median  SUVmax 
for each histologic subgroup using the log-rank test. The 
Cox proportional hazards model was used for multivariable 
analysis of prognostic factors, including age at diagnosis, 
sex, stage, and PET/CT  SUVmax. To determine additional 
associations between  SUVmax and survival outcomes, we 
examined the Cox regression model using the penalized 
spline smoothing method as described previously [15]. The 
performance of prognostic models was measured by Har-
rell’s c-index. We assessed model calibration by plotting 
the model-predicted- and actual observed 3- and 5-year RFS 
probabilities as calculated using the Kaplan–Meier method. 
The bootstrapping method with 1000 re-samples was used 
for adjusting bias and checking the interval validation. Sta-
tistical significance was set as P < 0.05 for all analyses. All 
statistical analyses were performed using SPSS version 20.0 
(SPSS, Chicago, IL, USA), SAS version 9.4 (SAS Institute 
Inc., Cary, NC, USA), and R package, version 3.2.4 (http://
www.R-proje ct.org).
Results
Patient characteristics
The baseline characteristics of the patients are summarized 
in Table 1. A total of 727 patients with pathologically con-
firmed AGC were analyzed. The majority of patients were 
male (68.0%), and the median age at diagnosis of AGC 
was 60 years (range 26–94) years. All patients underwent 
radical gastrectomy; 6.9% were pathological stage I, 26.3% 
were stage II, 57.4% were stage III, and 9.5% were stage 
IV. This study included 63 stage IV patients who presented 
with enlarged paraaortic lymph nodes that were observed by 
either preoperative PET/CT or CT. These patients underwent 
radical surgical resection with a curative aim accompanied 
by paraaortic lymph node dissection. Regarding the WHO 
classification, 36.9% had WMD histology, 48.0% had PD 
histology, and the remaining 15.1% had SRC histology. 
When patients were classified according to the Lauren clas-
sification, 46.8% had intestinal-type AGC, 44.6% had dif-
fuse type, and 8.7% had mixed type. Adjuvant chemotherapy 
was given in 88% of patients, excluding stage I patients (50 
patients), those with poor performance after surgery (16 
patients), and 21 patients who refused chemotherapy. All 
Table 1  Clinicopathological features and  SUVmax
WMD adenocarcinoma well to moderately differentiated, PD adeno-
carcinoma poorly differentiated, SRC signet ring cell carcinoma
Variables Total 
(n = 727)
n (%)
SUVmax
Mean (SD)
SUVmax
Median 
(range)
P value
Age (years)
 Median 
(range)
60.0 (26–94)
Sex
 Male 494 (68.0) 7.8 ± 5.1 6.3 (1.7–39.1) 0.274
 Female 233 (32.0) 7.4 ± 6.1 4.9 (1.3–42.6)
Location of tumor
 Upper 144 (19.8) 7.6 ± 5.0 6.0 (1.3–28.6) 0.250
 Middle 203 (27.9) 7.5 ± 5.6 5.9 (1.9–42.6)
 Lower 365 (50.2) 7.9 ± 5.7 6.1 (1.7–39.1)
 Whole 15 (2.1) 5.3 ± 2.5 4.4 (2.7–10.5)
Histology (WHO)
 WMD 268 (36.9) 9.2 ± 6.1 7.8 (1.7–42.6) < 0.001
 PD 349 (48.0) 7.5 ± 5.3 5.6 (1.3–36.0)
 SRC 110 (15.1) 4.5 ± 1.9 4.1 (1.9–11.8)
Histology (Lauren)
 Intestinal 340 (46.8) 9.2 ± 6.2 7.6 (1.7–42.6) < 0.001
 Diffuse 324 (44.6) 6.2 ± 4.0 4.6 (1.3–26.5)
 Mixed 63 (8.7) 7.6 ± 5.9 5.6 (2.2–28.6)
Stage
 I 50 (6.9) 5.8 ± 3.8 4.3 (1.7–18.9) 0.043
 II 191 (26.3) 8.3 ± 6.5 6.1 (2.1–42.6)
 III 417 (57.4) 7.7 ± 5.2 6.0 (1.9–36.0)
 IV 69 (9.5) 7.4 ± 4.6 5.9 (1.3–22.4)
T stage
 T2 93 (12.8%) 6.0 ± 3.5 4.7 (1.7–18.9) < 0.001
 T3 206 (28.3) 8.9 ± 6.2 7.1 (2.0–39.1)
 T4 428 (58.9) 7.5 ± 5.3 5.7 (1.3–42.6)
N stage
 N0 163 (22.4) 7.5 ± 6.3 4.9 (1.7–42.6) 0.427
 N1 135 (18.6) 8.2 ± 6.0 7.0 (2.0–39.1)
 N2 129 (17.7) 8.0 ± 5.3 6.3 (1.9–29.9)
 N3 300 (41.3) 7.4 ± 4.8 5.9 (1.3–32.6)
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patients who had adjuvant chemotherapy received fluoro-
uracil-based chemotherapy.
SUVmax and histologic subtype
This study only included patients with AGC, and 80% of 
all patients showed a positive 18F-FDG uptake (Supple-
mentary Figure 1). In terms of WHO classification, 86% of 
WMD, 81% of PD, and 68% of SRC showed positive 18F-
FDG uptake. According to the Lauren classification, 84% of 
intestinal type and 76% of diffuse type GC showed positive 
18F-FDG uptake. In terms of stage, 72% of stage I, 75% 
of stage II, 82% of stage III, and 94% of stage IV showed 
positive 18F-FDG uptake. Table 1 shows  SUVmax accord-
ing to various clinicopathologic variables. Notably,  SUVmax 
was significantly correlated with the histologic type of AGC 
by both the WHO and Lauren classifications (Fig. 1a). The 
mean  SUVmax of AGC patients with SRC histology was 
51% lower than that of AGC patients with WMD histology 
(4.5 ± 1.9 vs. 9.2 ± 6.1, P < 0.001). The majority of patients 
that had AGC with SRC histology had  SUVmax less than 5, 
whereas the majority of patients that had AGC with WMD 
histology had  SUVmax greater than 5. When the  SUVmax 
was analyzed according to the Lauren classification, patients 
with diffuse-type AGC, which mostly had SRC histology, 
had 33% lower  SUVmax than those with intestinal-type AGC, 
which mostly had WMD histology, (6.2 ± 4.0 vs. 9.2 ± 6.2, 
P < 0.001) (Fig. 1a). Moreover, the  SUVmax also correlated 
with the progression of stage, especially T stage (P < 0.001), 
but not nodal (N) stage (P = 0.427). Intriguingly, the  SUVmax 
correlated well with the maximal size of the tumor mass in 
AGC with WMD histology or intestinal type (Fig. 1b). How-
ever, the degree of correlation between  SUVmax and maximal 
tumor size was relatively weak in AGC with SRC histology 
or diffuse type. Collectively, these findings demonstrate the 
distinct tumor biology of AGC with WMD or SRC histol-
ogy, especially in terms of glucose metabolism.
The prognostic impact of  SUVmax according 
to histologic subtype
With the median follow-up duration of 32.5 months, 357 
(49%) patients recurred and 301 (49%) died. To evaluate 
the prognostic impact of each histologic subtype, the sur-
vival outcomes were compared between the high- and low-
SUVmax groups. The cut-off value was the median  SUVmax 
of each histologic group (Table 1). In terms of DFS, AGC 
patients with high  SUVmax had significantly shorter DFS if 
they had diffuse-type AGC or SRC histology (P < 0.001 and 
P < 0.001, respectively), while there were no differences in 
the DFS of AGC patients with intestinal type or WMD his-
tology (Fig. 2a, b). This was also true for OS; high  SUVmax 
only had a negative prognostic impact in AGC with diffuse 
type or SRC histology (P < 0.001 and P < 0.001, respec-
tively; Fig. 2c, d).
In the Cox proportional hazard model, which was 
adjusted for sex, age, T stage and N stage (Table  2), 
high  SUVmax was also negatively correlated with DFS 
Fig. 1  The preoperative 18F-FDG PET/CT SUVmax of advanced 
gastric cancer (AGC) according to histologic subtype. a The  SUVmax 
correlates with the histologic type of AGC by both the WHO and 
Lauren classifications. b The  SUVmax correlates well with the maxi-
mal size of the tumor in AGC with well to moderately differentiated 
(WMD) histology or intestinal type. *P < 0.05
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and OS in AGC patients with SRC histology (DFS: HR 
2.26, P = 0.005; OS: HR 2.61, P = 0.003). Moreover, 
high  SUVmax was negatively correlated with DFS and 
OS in AGC patients with diffuse-type AGC (DFS: HR 
2.17, P < 0.001; OS: HR 2.47, P < 0.001). This negative 
prognostic impact was not observed in AGC patients with 
WMD histology or intestinal type. In addition, even when 
the Cox regression model was applied with the exception 
of 16 stage IV patients, high  SUVmax was still a poor 
prognostic factor in SRC and diffuse-type gastric cancer 
(Supplementary Table 2).
To externally validate these findings, we also analyzed 
data from an independent institution. The same results 
were consistently observed in this validation cohort: (1) 
diffuse-type AGC with SRC histology had lower  SUVmax 
compared with intestinal-type AGC with WMD histology 
(Table S1); and (2) higher preoperative  SUVmax indicated 
poorer prognosis in AGC with SRC histology and diffuse 
type, but not in AGC patients with WMD histology and 
intestinal type (Fig. S2).
Taken together, these data confirmed that high  SUVmax 
has an independent negative prognostic role in AGC 
patients with SRC or diffuse-type AGC.
Prognostic implications of  SUVmax as a continuous 
variable (p‑spline curve)
To further investigate the role of  SUVmax as a continuous 
variable in survival analysis, p-spline curves for DFS were 
generated with the R program as described previously [15] 
after adjusting for sex, age, T stage and N stage (Fig. 3). 
The results were consistent with those from the Cox regres-
sion analysis with dichotomous variables. The p-spline 
curves showed a gradual increase in log HR as  SUVmax rises 
only for SRC histology (Fig. 3a, right) and for diffuse type 
(Fig. 3b, right). There was no definite trend for WMD and 
PD histology (Fig. 3a, left) or intestinal type (Fig. 3b, left). 
This confirmed that  SUVmax is a continuous variable that 
can predict DFS in AGC patients with SRC histology or 
diffuse-type AGC.
Generating a predictive model for recurrence 
probability based on preoperative  SUVmax in SRC 
or diffuse‑type AGC 
To predict recurrence after curative surgery more pre-
cisely for AGC, we tried to develop a novel predictive 
Fig. 2  Kaplan–Meier survival curves comparing the high- and low-
SUVmax groups in each histologic subtype. a, b High  SUVmax only 
had a negative prognostic impact on disease-free survival (DFS) in 
AGC with SRC histology or diffuse type. c, d High  SUVmax only had 
a negative prognostic impact on overall survival (OS) in AGC with 
SRC histology or diffuse type
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model based on preoperative  SUVmax. Recurrence-free 
probabilities at 1, 3, and 5 years were calculated for AGC 
with SRC histology (Fig. 4a) or diffuse type (Fig. 4b) 
after adjusting for sex, age, T stage and N stage. The RFS 
rate gradually decreased as  SUVmax increased, and the 
5-year RFS rate was less than 20% when the  SUVmax was 
greater than 5. To evaluate the performance of our predic-
tive model, we generated calibration curves (Fig. 5) that 
showed good agreement between the predicted and actual 
RFS; the bootstrap-corrected c-indices of the model were 
0.751 (95% CI 0.675–0.827) for AGC with SRC histology 
and 0.687 (95% CI 0.644–0.730) for diffuse-type AGC. 
Thus, we were able to generate and internally validate our 
novel predictive model for recurrence in AGC with SRC 
histology or diffuse-type AGC.
Discussion
Gastric cancer is increasingly recognized as a heteroge-
neous disease [11, 14, 16, 17]. Classically, it is classified 
according to its histology, i.e., as intestinal type or dif-
fuse type [18]. Intestinal-type GC is more predominant in 
older people and in men, whereas diffuse-type GC is more 
frequently found in younger women. Recently, genomic 
data is widely utilized to develop molecular classifica-
tion systems for GC. The TCGA Research Network pro-
posed a classification system to distinguish GC into four 
subtypes: (1) Epstein–Barr virus (EBV)-positive, with 
the highest DNA methylation levels; (2) microsatellite 
instability (MSI), characterized by hypermutated tumors; 
Table 2  Multivariable cox regression analysis of  SUVmax and its predictive impact on clinical outcomes according to histologic type
WMD adenocarcinoma well to moderately differentiated, PD adenocarcinoma poorly differentiated, SRC signet ring cell carcinoma, DFS dis-
ease-free survival, OS overall survival, AHR adjusted hazard ratio, CI confidence interval, ref reference
WHO classification WMD (n = 268) PD (n = 349) SRC (n = 110)
AHR (95% CI) P value AHR (95% CI) AHR (95% CI) P value
DFS
 Sex Female vs. male (ref) 0.97 (0.58–1.62) 0.916 0.94 (0.70–1.27) 0.686 0.78 (0.47–1.31) 0.354
 Age ≥ 65 vs. < 65 years (ref) 1.47 (0.98–2.18) 0.060 1.47 (1.09–1.97) 0.011 1.43 (0.83–2.47) 0.198
 T stage T4 vs. T2 + T3 (ref) 3.18 (2.08–4.87) < 0.001 2.54 (1.75–3.68) < 0.001 5.44 (1.93–15.34) 0.001
 N stage N1 + N2 + N3 vs. N0 (ref) 1.99 (1.14–3.46) 0.015 3.12 (1.75–5.55) < 0.001 2.25 (0.88–5.75) 0.090
 SUVmax High vs. low (ref) 0.92 (0.62–1.37) 0.680 1.09 (0.81–1.45) 0.570 2.26 (1.28–4.00) 0.005
OS
 Sex Female vs. male (ref) 0.95 (0.53–1.69) 0.854 1.00 (0.73–1.38) 1.000 0.86 (0.50–1.48) 0.574
 Age ≥ 65 vs. < 65 years (ref) 1.99 (1.27–3.14) 0.003 1.73 (1.26–2.37) 0.001 1.98 (1.12–3.50) 0.018
 T stage T4 vs. T2 + T3 (ref) 3.13 (1.92–5.09) < 0.001 2.87 (1.90–4.34) < 0.001 3.68 (1.29–10.48) 0.015
 N stage N1 + N2 + N3 vs. N0 (ref) 1.58 (0.87–2.89) 0.135 3.04 (1.59–5.85) < 0.001 2.22 (0.77–6.35) 0.138
 SUVmax High vs. low (ref) 0.90 (0.57–1.41) 0.638 1.39 (1.01–1.90) 0.043 2.61 (1.39–4.91) 0.003
Lauren classification Intestinal (n = 340) Mixed (n = 63) Diffuse (n = 324)
AHR (95% CI) P value AHR (95% CI) AHR (95% CI) P value
DFS
 Sex Female vs. male (ref) 1.02 (0.66–1.59) 0.922 0.65 (0.29–1.42) 0.277 0.97 (0.72–1.29) 0.814
 Age ≥ 65 vs. < 65 years (ref) 1.72 (1.21–2.44) 0.003 0.82 (0.38–1.77) 0.615 1.35 (1.00–1.83) 0.051
 T stage T4 vs. T2 + T3 (ref) 2.87 (1.96–4.20) < 0.001 3.63 (1.25–10.59) 0.018 3.09 (2.04–4.67) < 0.001
 N stage N1 + N2 + N3 vs. N0 (ref) 2.28 (1.37–3.81) 0.002 2.45 (0.67–8.92) 0.174 2.55 (1.44–4.53) 0.001
 SUVmax High vs. low (ref) 0.80 (0.56–1.13) 0.202 0.69 (0.32–1.53) 0.363 2.17 (1.60–2.95) < 0.001
OS
 Sex Female vs. male (ref) 1.09 (0.67–1.76) 0.742 0.77 (0.34–1.76) 0.536 0.99 (0.72–1.35) 0.932
 Age ≥ 65 vs. < 65 years (ref) 2.11 (1.42–3.14) < 0.001 1.27 (0.57–2.84) 0.558 1.74 (1.26–2.41) < 0.001
 T stage T4 vs. T2 + T3 (ref) 2.83 (1.84–4.37) < 0.001 4.13 (1.24–13.78) 0.021 3.13 (1.99–4.93) < 0.001
 N stage N1 + N2 + N3 vs. N0 (ref) 1.82 (1.05–3.14) 0.033 2.11 (0.57–7.81) 0.265 2.79 (1.41–5.52) 0.003
 SUVmax High vs. low (ref) 0.79 (0.53–1.18) 0.251 0.63 (0.27–1.46) 0.280 2.47 (1.77–3.46) < 0.001
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Fig. 3  p-spline curves for DFS after adjusting for sex, age, and dis-
ease stage. The p-spline curves show a gradual increase in log HR as 
 SUVmax rises only for SRC histology (a, right) and for diffuse type 
(b, right). There was no definite trend for WMD and PD histology (a, 
left) or intestinal type (b, left)
Fig. 4  Predictive model for recurrence based on preoperative  SUVmax in SRC (a) or diffuse-type AGC (b)
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(3) genomic stability (GS), which represents 20% of GC 
and comprises the majority of diffuse-type GC, has the 
most abundant CDH1 mutations and also shows increased 
RHOA mutations and CLDN18–ARHGAP fusions; and (4) 
chromosomal instability (CIN), which accounts for 50% of 
patients and is characterized by frequent TP53 mutations 
and high percentage of intestinal-type GC [16, 19].
However, current clinical practice does not take this het-
erogeneity into account; rather, GC is regarded as a sin-
gle type of malignancy, and a one-size-fits-all approach is 
applied. Although some previous studies have shown that 
the  SUVmax in PET/CT can differ markedly according to the 
histologic subtype, most studies still evaluate the prognostic 
impact of  SUVmax by considering GC to be a single disease 
entity rather than categorizing it into the various histologic 
subtypes. Not surprisingly, this has resulted in inconsisten-
cies between studies. Furthermore, despite the large num-
ber of studies that have already observed poor 18F-FDG 
PET uptake in patients with EGC only having mucosal or 
submucosal invasion, most studies still enroll patients with 
EGC. The largest preoperative study to date was reported 
by Lee et al., who evaluated the prognostic impact of PET/
CT in 271 GC patients [8]. Because approximately half of 
the enrolled patients had EGC, 45% of the patients had no 
detectable 18F-FDG uptake, and so only the remaining 149 
patients were available for further analysis. Consequently, 
the subgroup analysis was limited by the small sample size.
To overcome the limitations of previous studies, the 
present study prospectively collected data from more than 
700 patients with AGC while excluding patients with EGC. 
Moreover, to avoid oversimplification, the patients were 
divided and analyzed according to their histologic subtypes. 
Furthermore, the prognostic impact of  SUVmax was evalu-
ated not only as a dichotomous variable as determined by the 
median  SUVmax but also as a continuous variable by analyz-
ing p-spline curves. As a result, we were able to reveal the 
distinct prognostic impact of  SUVmax in 18F-FDG PET/CT 
according to histologic subtype.
First, diffuse-type AGC with SRC histology had lower 
 SUVmax compared with intestinal-type AGC with WMD his-
tology, which is in agreement with previous studies. Second, 
although the  SUVmax of diffuse-type AGC was lower than 
that of intestinal type, it had a significant prognostic impact 
in terms of survival outcome. On the other hand, the  SUVmax 
of intestinal-type AGC was more directly correlated with 
primary tumor size than diffuse-type AGC, but it did not 
have any prognostic impact. These finding provide a clue to 
explaining previous discrepancies regarding the prognos-
tic impact of 18F-FDG PET/CT in GC patients. Finally, we 
established and validated a novel model that utilizes the pre-
operative  SUVmax to predict tumor recurrence after surgery 
in patients with SRC or diffuse type, which may be a useful 
tool for clinical application.
Each histologic subtype of GC differs in its biology, espe-
cially in its metabolic profiles, which leads to different 18F-
FDG uptake patterns [20]. Among the various histologic 
types of GC, SRC stands out as a unique subtype due to 
its distinct molecular and metabolic features. In terms of 
the glucose transporter GLUT-1, SRC is reported to express 
GLUT-1 at lower levels than WMD adenocarcinoma, lead-
ing to reduced 18F-FDG uptake [21, 22]. In addition, SRC 
has lower levels of the pyruvate kinase M2 isoform (PKM2) 
compared with other histologic subtypes; PKM2 is respon-
sible for ATP production in the last step of glycolysis [12]. 
Furthermore, PKM2 expression is correlated with poor 
prognosis in SRC, while other subtypes are not. These meta-
bolic characteristics help explain the different patterns and 
prognostic values of 18F-FDG PET/CT in different histologic 
subtypes of GC, and our data highlight the importance of 
dividing GC into different histologic subtypes before PET/
CT analysis.
The main limitation of our study is the retrospective 
nature of data collection. Although we verified our findings 
Fig. 5  Calibration curves for the performance of predictive model in 
SRC (a) or diffuse-type AGC (b)
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in two independent cancer centers in Korea, more studies are 
needed to validate our findings in a prospective cohort. Espe-
cially, this study did not include patients who underwent 
preoperative treatment. Therefore, it is necessary to evalu-
ate the role of PET/CT in Western patients who received 
preoperative treatment with other studies. In addition, this 
study only included patients with AGC, thus most patients 
received adjuvant chemotherapy. There are limitations in 
analysis of the effect of adjuvant chemotherapy on the prog-
nostic remodeling. Second, volumetric PET parameters were 
not measured due to the large number of cases. Additional 
studies are needed to further evaluate the value of volumetric 
PET parameters rather than  SUVmax for predicting clinical 
outcomes in intestinal-type AGC.
In conclusion, this study demonstrated the differential 
patterns and prognostic impact of preoperative PET/CT 
 SUVmax in AGC according to histologic type. Although the 
 SUVmax did not have significant prognostic impact in WMD- 
and intestinal-type AGC, higher preoperative  SUVmax 
indicated poorer prognosis in SRC and diffuse-type AGC. 
Novel predictive models for recurrence probability can be 
provided based on the preoperative  SUVmax in patients with 
SRC or diffuse-type AGC. To validate these findings, we 
are preparing a prospective trial. If the results of this study 
are confirmed in a prospective trial, SRC or diffuse-type 
gastric cancer patients with high  SUVmax should be strati-
fied in adjuvant chemotherapy. Ultimately, a clinical trial 
in which novel or more intensive therapy approaches are 
applied to SRC and diffuse-type AGC patients with high 
 SUVmax should be performed.
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